Cas de Jongh, Miriam P van der Meulen, Emma C Gertsen, Hylke J F Brenkman, Johanna W van Sandick, Mark I van Berge Henegouwen, Suzanne S Gisbertz, Misha D P Luyer, Grard A P Nieuwenhuijzen, Jan J B van Lanschot, Sjoerd M Lagarde, Bas P L Wijnhoven, Wobbe O de Steur, Henk H Hartgrink, Jan H M B Stoot, Karel W E Hulsewe, Ernst Jan Spillenaar Bilgen, Marc J van Det, Ewout A Kouwenhoven, Freek Daams, Donald L van der Peet, Nicole C T van Grieken, Joos Heisterkamp, Boudewijn van Etten, Jan-Willem van den Berg, Jean-Pierre Pierie, Hasan H Eker, Annemieke Y Thijssen, Eric J T Belt, Peter van Duijvendijk, Eelco Wassenaar, Kevin P Wevers, Lieke Hol, Frank J Wessels, Nadia Haj Mohammad, Geert W J Frederix, Richard van Hillegersberg, Peter D Siersema, Erik Vegt, Jelle P Ruurda
BACKGROUND: Unnecessary D2-gastrectomy and associated costs can be prevented after detecting non-curable gastric cancer, but impact of staging on treatment costs is unclear. This study determined the cost impact of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG-PET/CT) and staging laparoscopy (SL) in gastric cancer staging. MATERIALS AND METHODS: In this cost analysis, four staging strategies were modeled in a decision tree: (1) 18F FDG-PET/CT first, then SL, (2) SL only, (3) 18F FDG-PET/CT only, and (4) neither SL nor 18F FDG-PET/CT...
March 25, 2024: Annals of Surgical Oncology